Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CD4CAR |
Synonyms | |
Therapy Description |
CD4CAR is a third-generation chimeric antigen receptor that targets CD4 and contains domains, CD28 and 4-1BB, and the signaling domain, CD3zeta, which potentially enhances immune response and leads to lysis of CD4-expressing tumor cells (PMID: 29348865, PMID: 31413761). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CD4CAR | CD4CAR is a third-generation chimeric antigen receptor that targets CD4 and contains domains, CD28 and 4-1BB, and the signaling domain, CD3zeta, which potentially enhances immune response and leads to lysis of CD4-expressing tumor cells (PMID: 29348865, PMID: 31413761). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06197672 | Phase I | CD4CAR | Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) As a Bridge to Allogeneic Stem Cell Transplant | Recruiting | USA | 0 |
NCT06071624 | Phase I | CD4CAR | Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML. | Recruiting | USA | 0 |
NCT03829540 | Phase I | CD4CAR | CD4CAR for CD4+ Leukemia and Lymphoma | Recruiting | USA | 0 |